NLRP3 INFLAMMASOME INHIBITORS Russian patent published in 2024 - IPC C07D237/14 C07D237/20 C07D401/14 C07D403/12 A61K31/501 A61P3/10 A61P9/00 A61P19/02 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to a compound of a certain structure or a pharmaceutically acceptable salt thereof, to a pharmaceutical composition having inhibitory activity on the NLRP3 inflammasome signaling pathway, and to the use of said compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease or disorder, wherein signal transmission mediated by NLRP3 promotes a pathological process and/or manifestation of symptoms and/or progression of said disease or disorder. Compound of formula (I)

(I),

or a pharmaceutically acceptable salt thereof, where R¹ is Cl, CH₃, -OCF₃ or CF₃, R² is H, halogen, C₁-C₄alkyl or halogen-C₁-C₄alkyl, R³, R⁴ are H, CN, C₁-C₄alkyl or halogen-C₁-C₄alkyl, Z is -O- or -NH-(CH₂)_n-, where n equals 0, 1 or 2, R⁵ is selected from the following structures:

,

where R^5a is independently selected from C₁-C₄alkyl, hydroxy-C₁-C₄alkyl and H, and R^5b is independently selected from -OH, C₁-C₄alkyl, hydroxy-C₁-C₄alkyl, H, halogen, oxo, halogen-C₁-C₄alkyl and -CO₂H, and m is 0 or 1, or R⁵ is selected from the following structures:

,

where R^5d is independently selected from H, halogen, halogen-C₁-C₄alkyl and C₁-C₄alkyl. Pharmaceutical composition having inhibitory activity on the inflammasome signaling pathway based on NOD-like receptor protein 3 (NLRP3), containing a therapeutically effective amount of the above compound or its pharmaceutically acceptable salt and one or more pharmaceutically acceptable carriers. Use of said compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease or disorder, wherein signal transmission mediated by NLRP3 promotes a pathological process and/or manifestation of symptoms and/or progression of said disease or disorder.

EFFECT: said group of inventions can be used to inhibit the NLRP3 inflammasome signaling pathway, treat or prevent diseases and/or disorders associated with NLRP3.

9 cl, 104 ex